美国 2012-2018 年艾滋病毒抗逆转录病毒治疗费用。
HIV Antiretroviral Therapy Costs in the United States, 2012-2018.
机构信息
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston.
National Alliance of State and Territorial AIDS Directors, Washington, DC.
出版信息
JAMA Intern Med. 2020 Apr 1;180(4):601-603. doi: 10.1001/jamainternmed.2019.7108.
Abstract
This study characterizes the costs of recommended initial HIV antiretroviral therapy regimens in the United States from 2012 to 2018 and the magnitude of cost changes over time.
摘要
本研究描述了 2012 年至 2018 年美国推荐的初始 HIV 抗逆转录病毒治疗方案的成本特征，以及随着时间的推移成本变化的幅度。
相似文献
1
HIV Antiretroviral Therapy Costs in the United States, 2012-2018.美国 2012-2018 年艾滋病毒抗逆转录病毒治疗费用。
JAMA Intern Med. 2020 Apr 1;180(4):601-603. doi: 10.1001/jamainternmed.2019.7108.
2
First-line antiretroviral therapy for HIV-infected children.针对感染艾滋病毒儿童的一线抗逆转录病毒疗法。
AIDS. 2015 Jun 19;29(10):1261-2. doi: 10.1097/QAD.0000000000000727.
3
Is antiretroviral therapy cost-effective in South Africa?抗逆转录病毒疗法在南非是否具有成本效益？
PLoS Med. 2006 Jan;3(1):e60. doi: 10.1371/journal.pmed.0030060. Epub 2006 Jan 31.
4
The cost of antiretroviral drugs and influence on prescribing policies.抗逆转录病毒药物的成本及其对处方政策的影响。
Int J STD AIDS. 2006 Aug;17(8):499-506. doi: 10.1258/095646206778145587.
5
Cost effectiveness of antiretrovirals - long term or short term?抗逆转录病毒药物的成本效益——长期还是短期？
Appl Health Econ Health Policy. 2009;7(4):225-7. doi: 10.1007/BF03256156.
6
Providing antiretroviral therapy for HIV infection.为艾滋病毒感染提供抗逆转录病毒疗法。
N Engl J Med. 2001 Mar 15;344(11):844-6. doi: 10.1056/NEJM200103153441112.
7
Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.卢旺达与艾滋病毒/艾滋病相关的卫生服务的经常性费用：对融资的影响。
Trop Med Int Health. 2008 Oct;13(10):1245-56. doi: 10.1111/j.1365-3156.2008.02142.x. Epub 2008 Aug 20.
8
Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: a substudy of the ANRS 106 Window Trial.HIV感染得到控制的患者间歇性与连续性抗逆转录病毒疗法的成本：法国国家艾滋病研究机构106号窗口期试验的一项子研究
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):416-21. doi: 10.1097/QAI.0b013e31818a657c.
9
A comparative analysis of outpatient costs in HIV treatment programs.艾滋病病毒治疗项目门诊费用的比较分析。
Rev Assoc Med Bras (1992). 2012 Sep-Oct;58(5):561-7.
10
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts.队列简介：低收入国家的抗逆转录病毒疗法（ART-LINC）：治疗队列的国际合作。
Int J Epidemiol. 2005 Oct;34(5):979-86. doi: 10.1093/ije/dyi164. Epub 2005 Sep 12.
引用本文的文献
1
Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data.丙型肝炎病毒早期治疗与消除计划期间的艾滋病护理成本趋势：一项索赔数据与瑞士艾滋病队列研究数据的关联研究
Open Forum Infect Dis. 2025 Jul 16;12(8):ofaf410. doi: 10.1093/ofid/ofaf410. eCollection 2025 Aug.
2
CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions.CCR5基因编辑与HIV免疫疗法：当前认知、挑战及未来方向
Front Immunol. 2025 Jun 18;16:1590690. doi: 10.3389/fimmu.2025.1590690. eCollection 2025.
3
Evaluating the Fiscal Impact of Antiretroviral Therapy for the Management of HIV in the United States 1987-2023.评估1987年至2023年美国抗逆转录病毒疗法用于治疗艾滋病毒的财政影响。
Clinicoecon Outcomes Res. 2025 May 28;17:407-418. doi: 10.2147/CEOR.S520050. eCollection 2025.
4
Free antiretrovirals as a key tool against the HIV pandemic: A systematic review.免费抗逆转录病毒药物作为抗击艾滋病大流行的关键工具：一项系统评价。
HIV Med. 2025 Sep;26(9):1329-1342. doi: 10.1111/hiv.70051. Epub 2025 May 28.
5
State AIDS Drug Assistance Programs' Contribution to the United States' Viral Suppression, 2015-2022.2015 - 2022年美国各州艾滋病药物援助项目对病毒抑制的贡献
medRxiv. 2025 Apr 6:2025.04.04.25325288. doi: 10.1101/2025.04.04.25325288.
6
The urgent need for newer drugs in routine HIV treatment in Africa: the case of Ghana.非洲常规艾滋病病毒治疗中对新型药物的迫切需求：以加纳为例。
Front Epidemiol. 2025 Mar 14;5:1523109. doi: 10.3389/fepid.2025.1523109. eCollection 2025.
7
Altered Host microRNAomics in HIV Infections: Therapeutic Potentials and Limitations.HIV 感染中宿主微小 RNA 组学的改变：治疗潜力和限制。
Int J Mol Sci. 2024 Aug 13;25(16):8809. doi: 10.3390/ijms25168809.
8
Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.自2018年以来，接受过治疗的HIV感染者更换或重新开始抗逆转录病毒治疗方案的医疗资源利用情况及治疗费用。
J Manag Care Spec Pharm. 2024 Aug;30(8):817-824. doi: 10.18553/jmcp.2024.30.8.817.
9
The Impact of Social Determinants of Health on Outcomes Among Individuals With HIV and Heart Failure: A Literature Review.健康的社会决定因素对艾滋病毒感染者和心力衰竭患者结局的影响：一项文献综述
Cureus. 2024 Mar 10;16(3):e55913. doi: 10.7759/cureus.55913. eCollection 2024 Mar.
10
The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review.多替拉韦联合替诺福韦和拉米夫定用于HIV治疗的成本效益：一项系统评价
Clinicoecon Outcomes Res. 2024 Jan 26;16:25-34. doi: 10.2147/CEOR.S439725. eCollection 2024.
本文引用的文献
1
The Affordable Care Act and the Burden of High Cost Sharing and Utilization Management Restrictions on Access to HIV Medications for People Living with HIV/AIDS.《平价医疗法案》以及高额费用分担和使用管理限制对艾滋病毒/艾滋病感染者获取艾滋病毒药物造成的负担
Popul Health Manag. 2016 Aug;19(4):272-8. doi: 10.1089/pop.2015.0076. Epub 2015 Nov 13.
Zotero 插件